Diagnostics – CrispIdea

Diagnostics

All
Diagnostics

November 25, 2020

Danaher Corp. (DHR – Q3FY20) – Quarter performance was positively affected by Cytiva acquisition.

Cytiva and Pall Biotech comprised most of the bioprocessing exposure; and collectively, these businesses increased orders by more than 60% in the quarter, driven by comprehensive offering across the bioprocessing workflow. Non-COVID-related bioprocessing activity remained healthy and in line with what the company saw over the last several quarters. Executive Summary Financial Statements – Income […]

September 22, 2020

Danaher Corp. (DHR – Q2FY20) – Cytiva acquisition to boost growth in FY21.

DHR revenues increased by 19.19% to $5.3bn in Q2FY20 and the acquisition of Cytiva contributed 21.5% to the increase in revenues. The company has increased the production capacity of diagnostic testing for COVID-19, since the test was launched, shipping more than 6mn test cartridge. Executive Summary Financial Statements – Income Statement and Forecast – Balance […]

July 21, 2020

Danaher Corp. (DHR – Q1FY20) – Cytiva acquisition to boost growth in FY21.

Danaher Corporation announced it completed the sale of its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel hollow fiber tangential flow filtration systems businesses to Sartorius AG for approximately $825 million. The combined revenue of the businesses, which were part of Danaher’s […]

June 11, 2019

Danaher Corp. (DHR) – GE Biopharma acquisition will lead to the growth in future

DHR sales grew by 4% to $4.9bn in Q1FY19 with 5.5% core revenue growth. The acquisitions increased revenues by 2.5%, while the impact of foreign currency translation decreased revenues by 4% during the quarter. Number of Pages – 39 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash Flow –Q1FY19 Results – […]